LEO LINBECK, III
Chairman of the Board and CEO of Aquinas Companies, LLC, a private, diversified holding company with annual revenues in excess of $500 million. In addition to serving on several corporate and business advisory boards, Mr. Linbeck is an Adjunct Professor at the Jones Graduate School of Business at Rice University, and Lecturer at the Stanford Graduate School of Business.
MAGNUS HÖÖK, PHD
A Director of Pulmotect and a Regents Professor at the Institute of Biosciences and Technology of Texas A&M, where he is the Director of the Center for Infection and Inflammation. Dr. Höök was recognized in 2005 as one of the top 5% funded scientist from the NIH for the past 25 years. Dr. Hook is an inventor and co-founder of Pulmotect. He is also a co-founder of Inhibitex, Inc., a publicly traded company. He has served on scientific advisory boards of several companies.
ATUL VARADHACHARY, MD, PHD
A Director of Pulmotect and the Managing Partner of Fannin Innovation Studio. Dr. Varadhachary brings over two decades of experience in life sciences and healthcare in both corporate and entrepreneurial settings. Previously he served as President of U.S. Operations at Reliance Life Sciences (RLS), part of the Reliance Group, India’s largest private sector enterprise with over $64 billion in annual revenues and for nine years as President & COO of Agennix, Inc., a late-stage biotechnology company where he helped lead a successful sale of the company. He also served as Senior Engagement Manager at the global management consulting firm, McKinsey & Co. He has served on the Board of Managers of the Harris Health System and as an Adjunct Professor at the Baylor College of Medicine and at the Jones Graduate School of Management at Rice University. He serves on the Life Sciences Advisory Committee of the Houston Technology Center, on the board of Reliance Life Sciences. and has served on the University of Houston Biotechnology Industrial Advisory Committee.
A Director of Pulmotect, Dr. Given is COO of Arrowhead Research, Inc. (Nasdaq: ARWR)and CEO of Leonardo Biosystems. Dr. Given recently retired as Chairman of the Board for ICON, plc (Nasdaq: ICLR). Until June of 2007, Dr. Given served as President and Chief Executive Officer and as a member of the Board of Directors of Encysive Pharmaceuticals. Previously he was with Johnson & Johnson for 9 years, serving in several capacities including President, International, Ortho-Clinical Diagnostics and as Group Vice President, Head of U.S. Marketing & Sales, Research & Development for Janssen Pharmaceutica. He has also held various executive and senior management positions at Sandoz Pharma Ltd., Sandoz Research Institute and Schering-Plough Corporation. Prior to entering the pharmaceutical industry, he was on the medical faculty at the University of Chicago.
A Director of Pulmotect, Dr. Benedyk has over 20 years of experience as a business development executive and consultant to life science companies. He previously headed The Pfizer Incubator (TPI) in La Jolla, CA where he held board positions with TPI and its portfolio companies, reviewed investment opportunities for the Incubator, and oversaw the TPI operations team. Before that, he held executive positions in Business Development and Intellectual Property at Ascenta Therapeutics, Optimer Pharmaceuticals (now Merck (NYSE: MRK)), Aurora Biosciences (now Vertex (NASDAQ: VRTX)) and Elan Pharmaceuticals (now Perrigo (NYSE: PRGO)). In addition, Dr. Benedyk founded and managed Rila Partners LLC, a life sciences strategy and business development advisory firm serving specialty care biotechnology companies. Dr. Benedyk received a PhD in Developmental Genetics from The Rockefeller University, where he was a Lucille P. Markey Graduate Fellow. He received his BS in Microbiology and Botany from the University of Michigan.